Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multiple Simon 2-Stage Study of Itacitinib Administered Orally to Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia Myelofibrosis (PET-MF)

NCT01633372 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT01633372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01633372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multiple Simon 2-Stage Study of Itacitinib Administered Orally to Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia Myelofibrosis (PET-MF)
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Completed
Start date
July 16, 2012
Completion date
June 29, 2021
Enrollment
87 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

mpn (myeloproliferative neoplasms)